1 July 2021 in Phoenix Medical Journal
Cytokines are secreted or membrane-bound proteins that act as mediators of intercellular signaling to regulate homeostasis of the immune system. They are produced by cells of innate and adaptive immunity in response to microbes and tumor antigens. Although there are several studies showing that IL2-330 gene polymorphism is associated with many types of cancer, as far as we know, there is a few study investigating the association between lung cancer and IL2-330 gene polymorphism. In this study, the role of IL2-330 gene polymorphism in the pathogenesis of lung cancer was investigated. 96 patients who were diagnosed with lung cancer and 96 age and sex matched healthy subjects participated in the study. Genomic DNA was isolated using the blood DNA isolation kit and the IL2-330 gene polymorphism was determined by polymerase chain reaction-confronting two pairs primer method. When analyzed for the lung cancer group and the healthy group according to IL2-330 gene polymorphism, genotype and allele frequencies were found to be similar in both groups (p>0,05). As a result; there was no statistically significant difference between the groups. Considering the ethnic diversity of lung cancer, the study needs verified in other populations.
10 January 2016 in International Journal of Medical and Pharmaceutical Case Reports
Background: In spite of resistance and limited response to chemotherapy, radiotherapy and immunotherapy, recent advances led to several targeted agents that showed the prolongation of progressive free survival. Due to these facts, surgical resection of multiple recurrences may be worthwhile in selected patients with kidney cancer. Case Report: We report a case of a 47-year-old man who underwent nephrectomy for T4N0 RCC, clear cell type, Fuhrman grade 2/4 in 2007. The patient afterward had multiple tumor recurrences. He underwent four metastasectomies, including liver, skin, rectum and scalp. And he received immunotherapy and multiple lines biological targeted treatments. He remains stable for 7 years after initial diagnosis. Conclusion: In patients with metastatic RCC, recurrent resections can be achieved safely and giving biological drugs may prolong survival. Close follow-up is important for the early detection of recurrence and complete resection of metastases can improve the outcomes of patients.